Physician profile
Stephen Behan
NPI 1225751381
$1,580.58
in general payments reported to CMS, 2019-2025
22 companies · $618 in 2025
The $618 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.18 · 2023: $414 · 2024: $517 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.55 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $371.19 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.41 | 2022-2025 | Farxiga, Breztri |
| Braeburn INC. | $136.52 | 2023-2025 | Brixadi |
| Novo Nordisk INC | $118.85 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $99.28 | 2023-2025 | |
| Indivior INC. | $94.00 | 2023-2025 | Sublocade |
| Lilly USA, LLC | $62.79 | 2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $59.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.34 | 2025 | Caplyta |
| Gilead Sciences, INC. | $46.17 | 2023-2024 | |
| Glaxosmithkline, LLC. | $45.43 | 2024-2025 | Pediarix, Rotarix, Bexsero |
| Vanda Pharmaceuticals INC. | $44.82 | 2024-2025 | Hetlioz, Fanapt |
| Alkermes, INC. | $39.37 | 2023-2025 | Vivitrol, Vivitrol |
| Dexcom, INC. | $34.36 | 2025 | Dexcom G6 Transmitter |
| Inari Medical, INC. | $29.99 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21.96 | 2025 | Spravato |
| Edwards Lifesciences Corporation | $20.75 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Organon LLC | $19.19 | 2023 | Nexplanon |
| Seqirus USA INC | $18.59 | 2025 | Fluad, Flucelvax |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.55 | 2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $17.28 | 2022 | |
| Recor Medical INC | $16.96 | 2024 | Paradise Renal Denervation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Behan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.